Adjuvant β-Lactam Therapy Combined with Vancomycin for Methicillin-Resistant Staphylococcus aureus Bacteremia: Does β-Lactam Class Matter?
We analyzed the impact of vancomycin (VAN) combined with adjuvant β-lactam therapy (Combo) on persistent (≥5 days) methicillin-resistant bacteremia versus VAN alone by using pooled data from two previously published observational studies ( = 156). Combo was inversely associated with persistent bact...
Gespeichert in:
Veröffentlicht in: | Antimicrobial agents and chemotherapy 2019-03, Vol.63 (3) |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | We analyzed the impact of vancomycin (VAN) combined with adjuvant β-lactam therapy (Combo) on persistent (≥5 days) methicillin-resistant
bacteremia versus VAN alone by using pooled data from two previously published observational studies (
= 156). Combo was inversely associated with persistent bacteremia (adjusted odds ratio, 0.460; 95% confidence interval, 0.229 to 0.923). Acute kidney injury was more common with Combo than with VAN (18.9% and 7.6%, respectively;
= 0.062). |
---|---|
ISSN: | 0066-4804 1098-6596 |
DOI: | 10.1128/AAC.02211-18 |